CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $948.19 million. The enterprise value is $871.16 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, before market open.
Earnings Date | May 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 67.82 million shares outstanding. The number of shares has increased by 13.79% in one year.
Current Share Class | 67.82M |
Shares Outstanding | 67.82M |
Shares Change (YoY) | +13.79% |
Shares Change (QoQ) | +12.14% |
Owned by Insiders (%) | 1.08% |
Owned by Institutions (%) | 35.32% |
Float | 67.09M |
Valuation Ratios
The trailing PE ratio is 50.36 and the forward PE ratio is 17.26.
PE Ratio | 50.36 |
Forward PE | 17.26 |
PS Ratio | 10.30 |
Forward PS | 8.59 |
PB Ratio | 8.24 |
P/TBV Ratio | 8.38 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | 50.71 |
EV / Sales | 10.55 |
EV / EBITDA | 58.38 |
EV / EBIT | 60.19 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.00.
Current Ratio | 4.21 |
Quick Ratio | 3.84 |
Debt / Equity | 0.00 |
Debt / EBITDA | 0.03 |
Debt / FCF | n/a |
Interest Coverage | 395.69 |
Financial Efficiency
Return on equity (ROE) is 19.87% and return on invested capital (ROIC) is 10.40%.
Return on Equity (ROE) | 19.87% |
Return on Assets (ROA) | 8.31% |
Return on Invested Capital (ROIC) | 10.40% |
Return on Capital Employed (ROCE) | 12.56% |
Revenue Per Employee | $1.27M |
Profits Per Employee | $264,308 |
Employee Count | 65 |
Asset Turnover | 0.76 |
Inventory Turnover | 0.81 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +163.77% in the last 52 weeks. The beta is 1.61, so CorMedix's price volatility has been higher than the market average.
Beta (5Y) | 1.61 |
52-Week Price Change | +163.77% |
50-Day Moving Average | 9.77 |
200-Day Moving Average | 9.60 |
Relative Strength Index (RSI) | 74.53 |
Average Volume (20 Days) | 1,449,211 |
Short Selling Information
The latest short interest is 8.45 million, so 12.46% of the outstanding shares have been sold short.
Short Interest | 8.45M |
Short Previous Month | 8.04M |
Short % of Shares Out | 12.46% |
Short % of Float | 12.60% |
Short Ratio (days to cover) | 3.87 |
Income Statement
In the last 12 months, CorMedix had revenue of $82.55 million and earned $17.18 million in profits. Earnings per share was $0.28.
Revenue | 82.55M |
Gross Profit | 78.59M |
Operating Income | 14.47M |
Pretax Income | n/a |
Net Income | 17.18M |
EBITDA | 14.92M |
EBIT | 14.47M |
Earnings Per Share (EPS) | $0.28 |
Full Income Statement Balance Sheet
The company has $77.50 million in cash and $476,587 in debt, giving a net cash position of $77.03 million or $1.14 per share.
Cash & Cash Equivalents | 77.50M |
Total Debt | 476,587 |
Net Cash | 77.03M |
Net Cash Per Share | $1.14 |
Equity (Book Value) | 114.89M |
Book Value Per Share | 1.70 |
Working Capital | 110.47M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$13.57 million and capital expenditures -$64,601, giving a free cash flow of -$13.63 million.
Operating Cash Flow | -13.57M |
Capital Expenditures | -64,601 |
Free Cash Flow | -13.63M |
FCF Per Share | -$0.20 |
Full Cash Flow Statement Margins
Gross margin is 95.19%, with operating and profit margins of 17.53% and 20.81%.
Gross Margin | 95.19% |
Operating Margin | 17.53% |
Pretax Margin | 20.81% |
Profit Margin | 20.81% |
EBITDA Margin | 18.08% |
EBIT Margin | 17.53% |
FCF Margin | n/a |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -13.79% |
Shareholder Yield | -13.79% |
Earnings Yield | 1.81% |
FCF Yield | -1.44% |
Analyst Forecast
The average price target for CorMedix is $15.00, which is 7.30% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $15.00 |
Price Target Difference | 7.30% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 49.05% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside | |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 0.2:1.
Last Split Date | Mar 26, 2019 |
Split Type | Reverse |
Split Ratio | 0.2:1 |
Scores
CorMedix has an Altman Z-Score of 6.54 and a Piotroski F-Score of 2.
Altman Z-Score | 6.54 |
Piotroski F-Score | 2 |